Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
| dc.contributor.author | Momattin, Hisham | |
| dc.contributor.author | Mohammed, Khurram | |
| dc.contributor.author | Zumla, Alimuddin | |
| dc.contributor.author | Memish, Ziad A. | |
| dc.contributor.author | Al-Tawfiq, Jaffar A. | |
| dc.contributor.department | Department of Medicine, Indiana University School of Medicine | en_US |
| dc.date.accessioned | 2020-06-10T18:28:17Z | |
| dc.date.available | 2020-06-10T18:28:17Z | |
| dc.date.issued | 2013-08-29 | |
| dc.description | This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. | |
| dc.description.abstract | The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections. | en_US |
| dc.eprint.version | Final published version | en_US |
| dc.identifier.citation | Momattin, H., Mohammed, K., Zumla, A., Memish, Z. A., & Al-Tawfiq, J. A. (2013). Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 17(10), e792–e798. https://doi.org/10.1016/j.ijid.2013.07.002 | en_US |
| dc.identifier.uri | https://hdl.handle.net/1805/22932 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Elsevier | en_US |
| dc.relation.isversionof | 10.1016/j.ijid.2013.07.002 | en_US |
| dc.relation.journal | International Journal of Infectious Diseases | en_US |
| dc.rights | Publisher Policy | * |
| dc.rights | This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. | |
| dc.source | PMC | en_US |
| dc.subject | MERS-CoV | en_US |
| dc.subject | Interferon | en_US |
| dc.subject | Ribavarin | en_US |
| dc.subject | SARS | en_US |
| dc.title | Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy | en_US |
| dc.type | Article | en_US |